|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-10-25
|
|
pubmed:abstractText |
In this pilot study, T-cell receptor B-variable (TCR-BV) gene usage in CD4 and CD8 T cells was assessed, by real-time polymerase chain reaction, as well as complementarity-determining region 3 (CDR3)-length polymorphism, before and after therapy in five patients with B-cell chronic lymphocytic leukaemia who received alemtuzumab (anti-CD52 monoclonal antibody) as first-line therapy. A decline in expression of most BV family genes in both CD4 and CD8 T cells was observed after alemtuzumab treatment, which was followed by a gradual increase in most BV families during long-term follow-up. After treatment, CDR3-length polymorphism showed an even more restricted pattern in CD4 T cells compared with pretreatment, with a shift towards a monoclonal/oligoclonal pattern. The clonally restricted pattern was significantly reduced in CD4 (P < 0.01) but not in CD8 T cells. This was followed by a gradual increase in the number of peaks within the CDR3 region of the different TCR-BV families, i.e. a polyclonal repertoire, during long-term follow-up. A restricted CDR3 pattern became even more restricted after treatment, but normalised during unmaintained follow-up. These results indicate that perturbations in the T-cell alterations following alemtuzumab are complex and include not only changes in CD4/CD8 T-cell numbers but also a highly restricted T-cell repertoire especially in CD4 T cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/CD52 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Complementarity Determining Regions,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Variable Region,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell...,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-1048
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
135
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
475-85
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16995884-Aged,
pubmed-meshheading:16995884-Antibodies, Monoclonal,
pubmed-meshheading:16995884-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16995884-Antibodies, Neoplasm,
pubmed-meshheading:16995884-Antigens, CD,
pubmed-meshheading:16995884-Antigens, Neoplasm,
pubmed-meshheading:16995884-Antineoplastic Agents,
pubmed-meshheading:16995884-CD4-Positive T-Lymphocytes,
pubmed-meshheading:16995884-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16995884-Complementarity Determining Regions,
pubmed-meshheading:16995884-DNA, Neoplasm,
pubmed-meshheading:16995884-Female,
pubmed-meshheading:16995884-Follow-Up Studies,
pubmed-meshheading:16995884-Genes, T-Cell Receptor beta,
pubmed-meshheading:16995884-Glycoproteins,
pubmed-meshheading:16995884-Humans,
pubmed-meshheading:16995884-Immunoglobulin Variable Region,
pubmed-meshheading:16995884-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:16995884-Male,
pubmed-meshheading:16995884-Middle Aged,
pubmed-meshheading:16995884-Pilot Projects,
pubmed-meshheading:16995884-Receptors, Antigen, T-Cell, alpha-beta,
pubmed-meshheading:16995884-T-Lymphocyte Subsets
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
|
|
pubmed:affiliation |
Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska (CCK), Karolinska Institutet, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
